25 XP   0   0   10

NeuBase Therapeutics Inc
Buy, Hold or Sell?

Let's analyse NeuBase Therapeutics Inc together

PenkeI guess you are interested in NeuBase Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of NeuBase Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about NeuBase Therapeutics Inc

I send you an email if I find something interesting about NeuBase Therapeutics Inc.

Quick analysis of NeuBase Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of NeuBase Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
20.0%

What is your share worth?

Current worth
$6.22
Expected worth in 1 year
$-26.90
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
$-33.12
Return On Investment
-7,638.4%

For what price can you sell your share?

Current Price per Share
$0.43
Expected price per share
$0.39 - $0.6
How sure are you?
50%

1. Valuation of NeuBase Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$0.43

Intrinsic Value Per Share

$-126.46 - $-54.66

Total Value Per Share

$-120.24 - $-48.44

2. Growth of NeuBase Therapeutics Inc (5 min.)




Is NeuBase Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$23.1m$54m-$30.8m-133.1%

How much money is NeuBase Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$34.2m-$25.6m-$8.5m-25.0%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of NeuBase Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#570 / 1016

Most Revenue
#777 / 1016

Most Profit
#826 / 1016

Most Efficient
#199 / 1016

What can you expect buying and holding a share of NeuBase Therapeutics Inc? (5 min.)

Welcome investor! NeuBase Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of NeuBase Therapeutics Inc.

What can you expect buying and holding a share of NeuBase Therapeutics Inc?

First you should know what it really means to hold a share of NeuBase Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of NeuBase Therapeutics Inc is $0.4336. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of NeuBase Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in NeuBase Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $6.22. Based on the TTM, the Book Value Change Per Share is $-8.28 per quarter. Based on the YOY, the Book Value Change Per Share is $6.11 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of NeuBase Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-9.06-2,088.9%-9.06-2,088.9%-6.81-1,571.4%-5.58-1,286.7%-4.92-1,135.4%
Usd Book Value Change Per Share-8.28-1,909.6%-8.28-1,909.6%6.111,408.5%0.024.3%0.56128.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.036.3%0.2966.1%
Usd Total Gains Per Share-8.28-1,909.6%-8.28-1,909.6%6.111,408.5%0.0510.6%0.84194.5%
Usd Price Per Share0.40-0.40-3.61-3.35-3.84-
Price to Earnings Ratio-0.04--0.04--0.53--0.85--1.38-
Price-to-Total Gains Ratio-0.05--0.05-0.59--9.92--3.93-
Price to Book Ratio0.06-0.06-0.25-0.63-1.07-
Price-to-Total Gains Ratio-0.05--0.05-0.59--9.92--3.93-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.4336
Number of shares2306
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.03
Usd Book Value Change Per Share-8.280.02
Usd Total Gains Per Share-8.280.05
Gains per Quarter (2306 shares)-19,093.70105.97
Gains per Year (2306 shares)-76,374.80423.87
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-76375-76385252172414
20-152750-152760505343838
30-229124-2291357575151262
40-305499-30551010096861686
50-381874-38188512618582110
60-458249-458260151410302534
70-534624-534635176612012958
80-610998-611010201813733382
90-687373-687385227015453806
100-763748-763760252317164230

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%5.015.00.025.0%
Book Value Change Per Share0.01.00.00.0%2.01.00.066.7%2.03.00.040.0%5.05.00.050.0%10.010.00.050.0%
Dividend per Share0.00.01.00.0%0.00.03.00.0%1.00.04.020.0%2.00.08.020.0%3.00.017.015.0%
Total Gains per Share0.01.00.00.0%2.01.00.066.7%2.03.00.040.0%5.05.00.050.0%10.010.00.050.0%

Fundamentals of NeuBase Therapeutics Inc

About NeuBase Therapeutics Inc

NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

Fundamental data was last updated by Penke on 2024-04-11 15:35:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of NeuBase Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit NeuBase Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare NeuBase Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of NeuBase Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--199.6%+199.6%
TTM--213.0%+213.0%
YOY--279.3%+279.3%
5Y--438.4%+438.4%
10Y--605.5%+605.5%
1.1.2. Return on Assets

Shows how efficient NeuBase Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare NeuBase Therapeutics Inc to the Biotechnology industry mean.
  • -104.7% Return on Assets means that NeuBase Therapeutics Inc generated $-1.05 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of NeuBase Therapeutics Inc:

  • The MRQ is -104.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -104.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-104.7%TTM-104.7%0.0%
TTM-104.7%YOY-40.0%-64.7%
TTM-104.7%5Y-105.0%+0.3%
5Y-105.0%10Y-85.7%-19.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-104.7%-13.5%-91.2%
TTM-104.7%-12.9%-91.8%
YOY-40.0%-11.8%-28.2%
5Y-105.0%-14.1%-90.9%
10Y-85.7%-16.0%-69.7%
1.1.3. Return on Equity

Shows how efficient NeuBase Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare NeuBase Therapeutics Inc to the Biotechnology industry mean.
  • -147.6% Return on Equity means NeuBase Therapeutics Inc generated $-1.48 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of NeuBase Therapeutics Inc:

  • The MRQ is -147.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -147.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-147.6%TTM-147.6%0.0%
TTM-147.6%YOY-47.5%-100.1%
TTM-147.6%5Y-128.3%-19.3%
5Y-128.3%10Y-102.6%-25.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-147.6%-16.9%-130.7%
TTM-147.6%-16.1%-131.5%
YOY-47.5%-15.1%-32.4%
5Y-128.3%-19.9%-108.4%
10Y-102.6%-20.9%-81.7%

1.2. Operating Efficiency of NeuBase Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient NeuBase Therapeutics Inc is operating .

  • Measures how much profit NeuBase Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare NeuBase Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of NeuBase Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--295.1%+295.1%
TTM--225.8%+225.8%
YOY--288.4%+288.4%
5Y--477.4%+477.4%
10Y--625.6%+625.6%
1.2.2. Operating Ratio

Measures how efficient NeuBase Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of NeuBase Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.090-3.090
TTM-3.264-3.264
YOY-3.783-3.783
5Y-5.679-5.679
10Y-7.894-7.894

1.3. Liquidity of NeuBase Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if NeuBase Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 5.92 means the company has $5.92 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of NeuBase Therapeutics Inc:

  • The MRQ is 5.916. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.916. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.916TTM5.9160.000
TTM5.916YOY13.096-7.180
TTM5.9165Y7.870-1.954
5Y7.87010Y6.575+1.296
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.9163.914+2.002
TTM5.9164.220+1.696
YOY13.0965.388+7.708
5Y7.8706.045+1.825
10Y6.5756.406+0.169
1.3.2. Quick Ratio

Measures if NeuBase Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare NeuBase Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 5.59 means the company can pay off $5.59 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of NeuBase Therapeutics Inc:

  • The MRQ is 5.588. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 5.588. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ5.588TTM5.5880.000
TTM5.588YOY12.611-7.023
TTM5.5885Y7.551-1.963
5Y7.55110Y6.373+1.178
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.5883.572+2.016
TTM5.5883.998+1.590
YOY12.6115.390+7.221
5Y7.5515.969+1.582
10Y6.3736.287+0.086

1.4. Solvency of NeuBase Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of NeuBase Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare NeuBase Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.29 means that NeuBase Therapeutics Inc assets are financed with 29.1% credit (debt) and the remaining percentage (100% - 29.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of NeuBase Therapeutics Inc:

  • The MRQ is 0.291. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.291. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.291TTM0.2910.000
TTM0.291YOY0.157+0.133
TTM0.2915Y0.160+0.130
5Y0.16010Y0.147+0.014
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2910.336-0.045
TTM0.2910.334-0.043
YOY0.1570.269-0.112
5Y0.1600.366-0.206
10Y0.1470.390-0.243
1.4.2. Debt to Equity Ratio

Measures if NeuBase Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare NeuBase Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 41.0% means that company has $0.41 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of NeuBase Therapeutics Inc:

  • The MRQ is 0.410. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.410. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.410TTM0.4100.000
TTM0.410YOY0.187+0.223
TTM0.4105Y0.203+0.207
5Y0.20310Y0.179+0.023
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4100.382+0.028
TTM0.4100.396+0.014
YOY0.1870.335-0.148
5Y0.2030.434-0.231
10Y0.1790.465-0.286

2. Market Valuation of NeuBase Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings NeuBase Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare NeuBase Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -0.04 means the investor is paying $-0.04 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of NeuBase Therapeutics Inc:

  • The EOD is -0.048. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.044. Based on the earnings, the company is expensive. -2
  • The TTM is -0.044. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.048MRQ-0.044-0.004
MRQ-0.044TTM-0.0440.000
TTM-0.044YOY-0.530+0.486
TTM-0.0445Y-0.852+0.809
5Y-0.85210Y-1.377+0.525
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.048-2.259+2.211
MRQ-0.044-2.569+2.525
TTM-0.044-2.664+2.620
YOY-0.530-4.120+3.590
5Y-0.852-6.258+5.406
10Y-1.377-6.171+4.794
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of NeuBase Therapeutics Inc:

  • The EOD is -0.055. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.050. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.050. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.055MRQ-0.050-0.005
MRQ-0.050TTM-0.0500.000
TTM-0.050YOY-0.663+0.613
TTM-0.0505Y-1.748+1.698
5Y-1.74810Y-2.478+0.730
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.055-2.924+2.869
MRQ-0.050-3.246+3.196
TTM-0.050-3.488+3.438
YOY-0.663-5.620+4.957
5Y-1.748-8.315+6.567
10Y-2.478-8.826+6.348
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of NeuBase Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.06 means the investor is paying $0.06 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of NeuBase Therapeutics Inc:

  • The EOD is 0.070. Based on the equity, the company is cheap. +2
  • The MRQ is 0.064. Based on the equity, the company is cheap. +2
  • The TTM is 0.064. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.070MRQ0.064+0.006
MRQ0.064TTM0.0640.000
TTM0.064YOY0.249-0.185
TTM0.0645Y0.627-0.564
5Y0.62710Y1.067-0.440
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.0701.851-1.781
MRQ0.0642.090-2.026
TTM0.0642.095-2.031
YOY0.2492.844-2.595
5Y0.6273.466-2.839
10Y1.0673.815-2.748
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of NeuBase Therapeutics Inc.

3.1. Institutions holding NeuBase Therapeutics Inc

Institutions are holding 12.768% of the shares of NeuBase Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Greenlight Capital, Inc3.65630.004913635000
2023-12-31UBS Group AG1.7624065724657240
2023-09-30Point72 Asset Management, L.P.1.6760.00026250000
2023-12-31Renaissance Technologies Corp1.52760.000156967569670
2023-12-31Carnegie Mellon University1.25950.041946970469700
2023-12-31Two Sigma Investments LLC0.5653021083210830
2023-12-31Vanguard Group Inc0.50901898100
2023-12-31Kestra Advisory Services, LLC0.44180.000116476-1500-8.3445
2023-09-30Jacob Asset Mgmt Of NY LLC0.41980.01921565500
2023-12-31Springbok Capital Management, LLC0.4170.00081555000
2023-12-31Geode Capital Management, LLC0.415201548200
2023-12-31Tower Research Capital LLC0.065602448160.6579
2023-12-31Bank of America Corp0.0216080400
2023-12-31First Manhattan Co. LLC0.00950353-353-50
2023-12-31Royal Bank of Canada0.0080300-362-54.6828
2023-12-31BlackRock Inc0.0023084-356-80.9091
2023-12-31Wells Fargo & Co0.00210791421.5385
2023-12-31Advisor Group Holdings, Inc.0.000602200
2023-12-31PNC Financial Services Group Inc0.000602100
2023-12-31Global Wealth Management Investment Advisory, Inc.0.000301200
Total 12.76050.0672475861+188203+39.5%

3.2. Funds holding NeuBase Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-01-31Vanguard Institutional Extnd Mkt Idx Tr0.50901898100
2023-12-31Jacob Discovery Fd Instl0.41980.05731565500
2023-12-31Fidelity Extended Market Index0.300801121600
2023-12-31Fidelity Series Total Market Index0.03820142500
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.03660136500
2023-12-31Fidelity Total Market Index0.03640135900
2023-12-31Northern Trust Extended Eq Market Idx0.0330123000
2023-12-31NT Ext Equity Mkt Idx Fd - L0.0330123000
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.02940109620.1828
2023-12-31Fidelity Nasdaq Composite Index0.0264098500
2023-12-31Spartan Total Market Index Pool E0.0133049700
2024-01-31State St US Ttl Mkt Indx SL Cl I0.0046017000
2023-12-31Northern Trust Wilshire 50000.00360135-1-0.7353
2023-12-31NT US Market Cap Idx Fd - L0.0036013500
2023-09-30BlackRock Extended Mkt Composite0.002308400
2023-12-31BlackRock Extended Equity Market K0.00207300
2023-12-31BNYM Mellon SL Market Completion UC10.0016058-1-1.6949
2023-12-31NT Ext Eq Mkt Indx Fd DC Lending Tier 50.001204400
2024-01-31State St US Extended Mkt Indx NL Cl C0.000602100
2023-12-31BNYM Mellon NSL Mkt Completion Fund Inst0.000602100
Total 1.4960.05735578000.0%

3.3. Insider Transactions

Insiders are holding 13.437% of the shares of NeuBase Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-09-14Corp SymetryxSELL1291081.44
2023-09-11Corp SymetryxSELL33761.44
2023-09-07Corp SymetryxSELL748521.8
2023-09-01Corp SymetryxBUY610760.98

4. Summary

4.1. Key Performance Indicators

The key performance indicators of NeuBase Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---8.280-8.2800%6.107-236%0.019-44604%0.557-1587%
Book Value Per Share--6.2196.2190%14.499-57%6.944-10%6.752-8%
Current Ratio--5.9165.9160%13.096-55%7.870-25%6.575-10%
Debt To Asset Ratio--0.2910.2910%0.157+85%0.160+81%0.147+98%
Debt To Equity Ratio--0.4100.4100%0.187+119%0.203+102%0.179+128%
Dividend Per Share----0%-0%0.027-100%0.287-100%
Eps---9.057-9.0570%-6.814-25%-5.579-38%-4.923-46%
Free Cash Flow Per Share---7.906-7.9060%-5.447-31%-3.975-50%-3.535-55%
Free Cash Flow To Equity Per Share---7.975-7.9750%5.906-235%0.782-1120%0.664-1301%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---54.656--------
Intrinsic Value_10Y_min---126.460--------
Intrinsic Value_1Y_max---3.963--------
Intrinsic Value_1Y_min---7.362--------
Intrinsic Value_3Y_max---13.061--------
Intrinsic Value_3Y_min---26.851--------
Intrinsic Value_5Y_max---23.550--------
Intrinsic Value_5Y_min---51.374--------
Market Cap1616985.456+9%1473037.9501473037.9500%13462448.100-89%12507770.340-88%14335083.240-90%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio0.070+9%0.0640.0640%0.249-74%0.627-90%1.067-94%
Pe Ratio-0.048-10%-0.044-0.0440%-0.530+1115%-0.852+1855%-1.377+3058%
Price Per Share0.434+9%0.3950.3950%3.610-89%3.354-88%3.844-90%
Price To Free Cash Flow Ratio-0.055-10%-0.050-0.0500%-0.663+1227%-1.748+3398%-2.478+4860%
Price To Total Gains Ratio-0.052-10%-0.048-0.0480%0.591-108%-9.923+20701%-3.932+8142%
Quick Ratio--5.5885.5880%12.611-56%7.551-26%6.373-12%
Return On Assets---1.047-1.0470%-0.400-62%-1.050+0%-0.857-18%
Return On Equity---1.476-1.4760%-0.475-68%-1.283-13%-1.026-30%
Total Gains Per Share---8.280-8.2800%6.107-236%0.046-18119%0.843-1082%
Usd Book Value--23191880.00023191880.0000%54069773.000-57%25897360.400-10%25180185.700-8%
Usd Book Value Change Per Share---8.280-8.2800%6.107-236%0.019-44604%0.557-1587%
Usd Book Value Per Share--6.2196.2190%14.499-57%6.944-10%6.752-8%
Usd Dividend Per Share----0%-0%0.027-100%0.287-100%
Usd Eps---9.057-9.0570%-6.814-25%-5.579-38%-4.923-46%
Usd Free Cash Flow---29483677.000-29483677.0000%-20312099.000-31%-14822648.200-50%-13183828.300-55%
Usd Free Cash Flow Per Share---7.906-7.9060%-5.447-31%-3.975-50%-3.535-55%
Usd Free Cash Flow To Equity Per Share---7.975-7.9750%5.906-235%0.782-1120%0.664-1301%
Usd Market Cap1616985.456+9%1473037.9501473037.9500%13462448.100-89%12507770.340-88%14335083.240-90%
Usd Price Per Share0.434+9%0.3950.3950%3.610-89%3.354-88%3.844-90%
Usd Profit---34234561.000-34234561.0000%-25667406.000-25%-23497463.600-31%-19704552.900-42%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---8.280-8.2800%6.107-236%0.046-18119%0.843-1082%
 EOD+5 -3MRQTTM+0 -0YOY+2 -275Y+4 -2710Y+3 -28

4.2. Fundamental Score

Let's check the fundamental score of NeuBase Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.048
Price to Book Ratio (EOD)Between0-10.070
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than15.588
Current Ratio (MRQ)Greater than15.916
Debt to Asset Ratio (MRQ)Less than10.291
Debt to Equity Ratio (MRQ)Less than10.410
Return on Equity (MRQ)Greater than0.15-1.476
Return on Assets (MRQ)Greater than0.05-1.047
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of NeuBase Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5034.402
Ma 20Greater thanMa 500.515
Ma 50Greater thanMa 1000.708
Ma 100Greater thanMa 2000.712
OpenGreater thanClose0.415
Total0/5 (0.0%)



Latest Balance Sheet

Balance Sheet of 2022-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets32,693
Total Liabilities9,502
Total Stockholder Equity23,192
 As reported
Total Liabilities 9,502
Total Stockholder Equity+ 23,192
Total Assets = 32,693

Assets

Total Assets32,693
Total Current Assets24,649
Long-term Assets8,045
Total Current Assets
Cash And Cash Equivalents 23,153
Net Receivables 128
Inventory -128
Other Current Assets 1,496
Total Current Assets  (as reported)24,649
Total Current Assets  (calculated)24,649
+/-0
Long-term Assets
Property Plant Equipment 7,772
Other Assets 273
Long-term Assets  (as reported)8,045
Long-term Assets  (calculated)8,045
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities4,166
Long-term Liabilities5,335
Total Stockholder Equity23,192
Total Current Liabilities
Short-term Debt 661
Accounts payable 1,843
Other Current Liabilities 1,663
Total Current Liabilities  (as reported)4,166
Total Current Liabilities  (calculated)4,166
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt5,335
Long-term Liabilities  (as reported)5,335
Long-term Liabilities  (calculated)5,335
+/-0
Total Stockholder Equity
Common Stock3
Retained Earnings -102,744
Other Stockholders Equity 125,933
Total Stockholder Equity (as reported)23,192
Total Stockholder Equity (calculated)23,192
+/-0
Other
Capital Stock3
Cash and Short Term Investments 23,153
Common Stock Shares Outstanding 1,624
Liabilities and Stockholders Equity 32,693
Net Debt -17,157
Net Invested Capital 23,192
Net Tangible Assets 23,192
Net Working Capital 20,482
Property Plant and Equipment Gross 9,068
Short Long Term Debt Total 5,996



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2022-09-302021-09-302020-09-302019-09-302018-09-302017-09-302016-09-302015-09-302014-09-302013-09-302012-09-302011-09-302010-09-302009-09-302008-09-302007-09-302006-09-302005-09-302004-09-302003-09-30
> Total Assets 
1,299
1,827
1,735
387
702
181
1,231
1,412
1,413
3,517
5,744
32,025
46,371
29,445
27,929
11,626
12,531
34,444
64,168
32,693
32,69364,16834,44412,53111,62627,92929,44546,37132,0255,7443,5171,4131,4121,2311817023871,7351,8271,299
   > Total Current Assets 
289
302
40
0
200
96
346
607
692
2,851
5,168
13,354
29,036
13,285
13,024
3,998
11,029
32,809
54,929
24,649
24,64954,92932,80911,0293,99813,02413,28529,03613,3545,1682,85169260734696200040302289
       Cash And Cash Equivalents 
0
0
0
0
197,000
96
346
507
470
2,632
5,123
13,220
28,697
12,547
12,801
3,750
10,314
31,992
52,893
23,153
23,15352,89331,99210,3143,75012,80112,54728,69713,2205,1232,63247050734696197,0000000
       Short-term Investments 
281
291
2
372
328
0
0
0
0
0
0
0
0
0
0
0
0
324
0
0
003240000000000003283722291281
       Net Receivables 
7
11
38
0
-26,000
0
0
65
179
0
0
0
0
0
0
0
0
0
0
128
12800000000001796500-26,000038117
       Other Current Assets 
0
0
0
0
-128
0
0
35
5
218
45
134
339
738
223
248
266
295
2,035,247
1,496
1,4962,035,2472952662482237383391344521853500-1280000
   > Long-term Assets 
135
163
144
0
500
85
885
805
721
667
576
18,671
17,335
16,160
14,905
7,628
1,502
1,636
9,239
8,045
8,0459,2391,6361,5027,62814,90516,16017,33518,671576667721805885855000144163135
       Property Plant Equipment 
135
163
144
0
61
0
0
24
19
43
30
104
249
199
64
16
431
1,167
8,409
7,772
7,7728,4091,16743116641992491043043192400610144163135
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
741
741
741
741
0
0
0
0
0
0000074174174174100000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
3
0
0
0
0
586
324
416
0
04163245860000300000000000
       Intangible Assets 
0
0
0
0
0
0
800
780
702
624
0
17,810
16,333
15,208
14,088
7,612
146
0
0
0
0001467,61214,08815,20816,33317,8100624702780800000000
       Long-term Assets Other 
-135
-163
-144
0
439
85
0
0
0
0
546
12
12
12
12
7,628
339
145
414
273
2734141453397,628121212125460000854390-144-163-135
> Total Liabilities 
375
618
555
396
965
148
618
1,794
6,195
1,091
480
5,273
3,880
4,482
5,084
725
2,502
3,150
10,098
9,502
9,50210,0983,1502,5027255,0844,4823,8805,2734801,0916,1951,794618148965396555618375
   > Total Current Liabilities 
48
46
37
0
640
148
338
407
6,195
1,091
480
5,273
3,880
4,482
4,934
725
2,502
3,150
4,194
4,166
4,1664,1943,1502,5027254,9344,4823,8805,2734801,0916,1954073381486400374648
       Short-term Debt 
48
46
37
0
0
0
180
69
0
22
14
44
48
88
106
73
123
139
639
661
661639139123731068848441422069180000374648
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
88
106
73
123
139
148
0
014813912373106880000000000000
       Accounts payable 
0
0
0
0
240,000
56
77
0
0
0
0
352
1,592
4,394
0
652
1,477
1,505
1,808
1,843
1,8431,8081,5051,47765204,3941,59235200007756240,0000000
       Other Current Liabilities 
-48
-46
-37
0
-239,360
92
81
338
6,195
1,069
466
5,229
3,832
4,394
4,828
652
496
950
1,748
1,663
1,6631,7489504966524,8284,3943,8325,2294661,0696,1953388192-239,3600-37-46-48
   > Long-term Liabilities 
13
32
23
0
330
56
280
1,388
0
22
14
44
48
88
150
73
1,600
1,645
5,904
5,335
5,3355,9041,6451,60073150884844142201,388280563300233213
> Total Stockholder Equity
924
1,209
1,180
-8
-263
33
613
-382
-4,782
2,426
5,264
26,752
42,491
24,963
22,845
10,901
10,029
31,295
54,070
23,192
23,19254,07031,29510,02910,90122,84524,96342,49126,7525,2642,426-4,782-38261333-263-81,1801,209924
   Common Stock
907
907
965
0
21,366
21,637
3
4
4
5
2
3
3
3
6
6
2
2
3
3
3322663332544321,63721,3660965907907
   Retained Earnings 
94
379
301
-124
-21,629
-21,604
-22,468
-21,974
-21,629
-28,530
-21,629
-43,314
-58,511
-84,278
-108,089
-121,326
-27,000
-43,559
-68,968
-102,744
-102,744-68,968-43,559-27,000-121,326-108,089-84,278-58,511-43,314-21,629-28,530-21,629-21,974-22,468-21,604-21,629-12430137994
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
70,063
100,999
109,238
130,928
132,221
37,028
0
0
0
00037,028132,221130,928109,238100,99970,06300000000000
   Treasury Stock00000000000000000000
   Other Stockholders Equity 
-78
-78
-86
115
0
0
23,078
21,588
16,842
30,951
39,445
70,110
101,086
109,389
131,036
132,315
37,028
74,851
123,034
125,933
125,933123,03474,85137,028132,315131,036109,389101,08670,11039,44530,95116,84221,58823,07800115-86-78-78



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2022-09-30)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-1,263
Gross Profit-1,263-1,263
 
Operating Income (+$)
Gross Profit-1,263
Operating Expense-33,318
Operating Income-33,318-34,581
 
Operating Expense (+$)
Research Development21,449
Selling General Administrative11,870
Selling And Marketing Expenses0
Operating Expense33,31833,318
 
Net Interest Income (+$)
Interest Income149
Interest Expense-24
Other Finance Cost-0
Net Interest Income125
 
Pretax Income (+$)
Operating Income-33,318
Net Interest Income125
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-33,776-32,860
EBIT - interestExpense = -33,342
-33,776
-34,211
Interest Expense24
Earnings Before Interest and Taxes (EBIT)-33,318-33,752
Earnings Before Interest and Taxes (EBITDA)-32,490
 
After tax Income (+$)
Income Before Tax-33,776
Tax Provision-0
Net Income From Continuing Ops-33,776-33,776
Net Income-34,235
Net Income Applicable To Common Shares-33,776
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses33,318
Total Other Income/Expenses Net-458-125
 

Technical Analysis of NeuBase Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of NeuBase Therapeutics Inc. The general trend of NeuBase Therapeutics Inc is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine NeuBase Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of NeuBase Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.59 < 0.5925 < 0.6.

The bearish price targets are: 0.39 > 0.39.

Tweet this
NeuBase Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of NeuBase Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

NeuBase Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of NeuBase Therapeutics Inc. The current macd is -0.10183238.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the NeuBase Therapeutics Inc price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for NeuBase Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the NeuBase Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
NeuBase Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartNeuBase Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of NeuBase Therapeutics Inc. The current adx is 36.18.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell NeuBase Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
NeuBase Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of NeuBase Therapeutics Inc. The current sar is 0.64001135.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
NeuBase Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of NeuBase Therapeutics Inc. The current rsi is 34.40. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
NeuBase Therapeutics Inc Daily Relative Strength Index (RSI) ChartNeuBase Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of NeuBase Therapeutics Inc. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the NeuBase Therapeutics Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
NeuBase Therapeutics Inc Daily Stochastic Oscillator ChartNeuBase Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of NeuBase Therapeutics Inc. The current cci is -38.2912666.

NeuBase Therapeutics Inc Daily Commodity Channel Index (CCI) ChartNeuBase Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of NeuBase Therapeutics Inc. The current cmo is -27.59976875.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
NeuBase Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartNeuBase Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of NeuBase Therapeutics Inc. The current willr is -42.09827357.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that NeuBase Therapeutics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
NeuBase Therapeutics Inc Daily Williams %R ChartNeuBase Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of NeuBase Therapeutics Inc.

NeuBase Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of NeuBase Therapeutics Inc. The current atr is 0.06182597.

NeuBase Therapeutics Inc Daily Average True Range (ATR) ChartNeuBase Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of NeuBase Therapeutics Inc. The current obv is 111,584,048.

NeuBase Therapeutics Inc Daily On-Balance Volume (OBV) ChartNeuBase Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of NeuBase Therapeutics Inc. The current mfi is 57.62.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
NeuBase Therapeutics Inc Daily Money Flow Index (MFI) ChartNeuBase Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for NeuBase Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-30SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-01RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-04ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-28MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-30CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-31SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-20CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-18CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-19WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-21RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-08MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-16MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-17RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.

6.3. Candlestick Patterns

NeuBase Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of NeuBase Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5034.402
Ma 20Greater thanMa 500.515
Ma 50Greater thanMa 1000.708
Ma 100Greater thanMa 2000.712
OpenGreater thanClose0.415
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of NeuBase Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on NeuBase Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about NeuBase Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about NeuBase Therapeutics Inc

I send you an email if I find something interesting about NeuBase Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about NeuBase Therapeutics Inc.

Receive notifications about NeuBase Therapeutics Inc in your mailbox!